Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022664832> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W2022664832 endingPage "390" @default.
- W2022664832 startingPage "390" @default.
- W2022664832 abstract "Sunitinib is a potent oral tyrosine kinase inhibitor of VEGFRs, KIT, and PDGFRs. In a single arm phase II trial, sunitinib has demonstrated its potential activity in refractory thymic carcinoma (TC) and thymoma (T). Taking advantage of the French RYTHMIC network prospective database, we investigated the off-label efficacy of sunitinib in previously-treated thymic epithelial tumors (TETs) patients not included in a clinical trial.RYTHMIC database started in 2012, and prospectively collects clinical, imaging, treatment, and follow-up data of all patients diagnosed with TET, for whom management is discussed at a national multidisciplinary tumor board. All patients who received sunitinib were selected for this analysis.28 patients from 7 institutions were identified, including 20 TC and 8 T; 32% of patients were females, and median age was 50 years. Fifteen patients (54%) received sunitinib as ≥4th line treatment. The initial daily dose of sunitinib was 50 mg in 11 patients, 37.5 mg in 16 patients and 25 mg in 1 patient. Sunitinib adverse events were all manageable and tolerable; 8 patients had to stop sunitinib due to toxicity after a median duration of treatment of 2.7 months. In the overall population, disease control rate was of 63% (86% for T, and 55% for TC); overall response rate was 22% (29% for T, and 20% for TC). Median PFS in the whole population was 3.7 months (5.4 months for T, and 3.3 months for TC, p = 0.097). The median overall survival in the whole population was 15.4 months: survival was not reached for T, and was 12.3 months for TC patients (p = 0.043).Sunitinib is an active treatment in TETs irrespective of histological subtype, supporting the use of tyrosine kinase inhibitors with anti-angiogenic activity as alternative treatment options in refractory disease." @default.
- W2022664832 created "2016-06-24" @default.
- W2022664832 creator A5030848587 @default.
- W2022664832 creator A5038983218 @default.
- W2022664832 creator A5047402116 @default.
- W2022664832 creator A5049509860 @default.
- W2022664832 creator A5054170239 @default.
- W2022664832 creator A5078591113 @default.
- W2022664832 creator A5079350912 @default.
- W2022664832 creator A5090471467 @default.
- W2022664832 creator A5030135770 @default.
- W2022664832 date "2007-09-01" @default.
- W2022664832 modified "2023-10-16" @default.
- W2022664832 title "6606 POSTER Three drug regimen in SCLC-ED patients: a phase II study" @default.
- W2022664832 doi "https://doi.org/10.1016/s1359-6349(07)71434-9" @default.
- W2022664832 hasPublicationYear "2007" @default.
- W2022664832 type Work @default.
- W2022664832 sameAs 2022664832 @default.
- W2022664832 citedByCount "0" @default.
- W2022664832 crossrefType "journal-article" @default.
- W2022664832 hasAuthorship W2022664832A5030135770 @default.
- W2022664832 hasAuthorship W2022664832A5030848587 @default.
- W2022664832 hasAuthorship W2022664832A5038983218 @default.
- W2022664832 hasAuthorship W2022664832A5047402116 @default.
- W2022664832 hasAuthorship W2022664832A5049509860 @default.
- W2022664832 hasAuthorship W2022664832A5054170239 @default.
- W2022664832 hasAuthorship W2022664832A5078591113 @default.
- W2022664832 hasAuthorship W2022664832A5079350912 @default.
- W2022664832 hasAuthorship W2022664832A5090471467 @default.
- W2022664832 hasConcept C121608353 @default.
- W2022664832 hasConcept C126322002 @default.
- W2022664832 hasConcept C141071460 @default.
- W2022664832 hasConcept C143998085 @default.
- W2022664832 hasConcept C197934379 @default.
- W2022664832 hasConcept C2778820342 @default.
- W2022664832 hasConcept C2779490328 @default.
- W2022664832 hasConcept C2781413609 @default.
- W2022664832 hasConcept C2908647359 @default.
- W2022664832 hasConcept C31760486 @default.
- W2022664832 hasConcept C535046627 @default.
- W2022664832 hasConcept C71924100 @default.
- W2022664832 hasConcept C90924648 @default.
- W2022664832 hasConcept C99454951 @default.
- W2022664832 hasConceptScore W2022664832C121608353 @default.
- W2022664832 hasConceptScore W2022664832C126322002 @default.
- W2022664832 hasConceptScore W2022664832C141071460 @default.
- W2022664832 hasConceptScore W2022664832C143998085 @default.
- W2022664832 hasConceptScore W2022664832C197934379 @default.
- W2022664832 hasConceptScore W2022664832C2778820342 @default.
- W2022664832 hasConceptScore W2022664832C2779490328 @default.
- W2022664832 hasConceptScore W2022664832C2781413609 @default.
- W2022664832 hasConceptScore W2022664832C2908647359 @default.
- W2022664832 hasConceptScore W2022664832C31760486 @default.
- W2022664832 hasConceptScore W2022664832C535046627 @default.
- W2022664832 hasConceptScore W2022664832C71924100 @default.
- W2022664832 hasConceptScore W2022664832C90924648 @default.
- W2022664832 hasConceptScore W2022664832C99454951 @default.
- W2022664832 hasIssue "4" @default.
- W2022664832 hasLocation W20226648321 @default.
- W2022664832 hasOpenAccess W2022664832 @default.
- W2022664832 hasPrimaryLocation W20226648321 @default.
- W2022664832 hasRelatedWork W134447636 @default.
- W2022664832 hasRelatedWork W1992943540 @default.
- W2022664832 hasRelatedWork W2397703782 @default.
- W2022664832 hasRelatedWork W2414755921 @default.
- W2022664832 hasRelatedWork W2590359217 @default.
- W2022664832 hasRelatedWork W2603291805 @default.
- W2022664832 hasRelatedWork W2737644370 @default.
- W2022664832 hasRelatedWork W2922116982 @default.
- W2022664832 hasRelatedWork W2951745405 @default.
- W2022664832 hasRelatedWork W3088178260 @default.
- W2022664832 hasVolume "5" @default.
- W2022664832 isParatext "false" @default.
- W2022664832 isRetracted "false" @default.
- W2022664832 magId "2022664832" @default.
- W2022664832 workType "article" @default.